Did management answer the analysts?
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →✓ Verified against BSE filing
Bajaj Finserv reported a mixed Q3 FY25. Consolidated revenue grew 10% YoY to INR 32,042 crore, while PAT rose 3% to INR 2,231 crore. Excluding unrealized MTM, core PAT grew 23%. BAGIC delivered strong performance with 39% PAT growth and a combined ratio of 101.1%, though top-line growth was distorted by regulatory changes. BALIC saw muted individual-rated new business growth due to product mix recalibration and new surrender regulations, but retail protection surged 96% YoY. Bajaj Finance posted a healthy quarter with 26% net income growth and ROE of 19.08%. Management emphasized a shift toward profitable growth, particularly in life insurance, with VNB growth prioritized over top-line. Key risks include prolonged disruption from surrender regulation adjustments and competitive pressure in health insurance. The Allianz JV exit discussions remain preliminary.
बजाज फिनसर्व की तीसरी तिमाही के नतीजे मिले-जुले रहे। कंपनी की कुल कमाई पिछले साल से 10% बढ़कर 32,042 करोड़ रुपये हो गई, जबकि शुद्ध लाभ (PAT) 3% बढ़कर 2,231 करोड़ रुपये रहा। अस्थायी बाजार बदलावों को छोड़कर, मुख्य लाभ 23% बढ़ा। बजाज ऑलियंज जनरल इंश्योरेंस ने 39% लाभ वृद्धि दी, लेकिन नियमों में बदलाव से कमाई पर असर पड़ा। बजाज ऑलियंज लाइफ इंश्योरेंस में नए नियमों के कारण व्यक्तिगत बीमा की बिक्री धीमी रही, लेकिन रिटेल सुरक्षा बीमा में 96% उछाल आया। बजाज फाइनेंस ने 26% लाभ वृद्धि और 19.08% रिटर्न दिया। कंपनी अब लाइफ इंश्योरेंस में मुनाफे पर ध्यान दे रही है। मुख्य जोखिमों में नए नियमों का असर और स्वास्थ्य बीमा में प्रतिस्पर्धा शामिल है।
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →0 delivered, 0 close, 3 missed.
View Promises →Surrender regulation disruption in life insurance
View Risks →Full transcript text is available on this route.
Read Transcript →Improved from 102.9% in Q3 FY24, reflecting better underwriting discipline.
Retail protection premium grew to INR 108 crore in Q3, driven by product mix shift.
VNB growth muted due to product mix changes and surrender regulation impact.
Highest-ever quarterly new loans, adding 5.3 million new customers.
Management expects VNB to grow faster than top-line due to product structure changes and focus on profitability.
Continued focus on profitable growth with combined ratio superior to industry average.
Management committed to bringing down loan losses in the coming year.
Management expects VNB margins to improve in H2 as product mix rebalances away from ULIPs and commission deferrals take effect.
The marketplace business expects to break even on a cash basis within the next couple of quarters.
BFL plans to invest ₹500-600 crore in health tech and asset management over the next 18 months.
Management expects core premium growth to continue outpacing the industry, driven by disciplined underwriting.
New surrender value guidelines have impacted product mix and distribution, with agency channel taking longer to adjust.
IRDAI capping senior citizen premium hikes and EOM limits may pressure margins, though Bajaj is well-positioned.
VNB margins fell 3.8pp YoY to 9.2% due to higher ULIP sales; new surrender value norms may further pressure margins.
No TP price hike for three years has led to underwriting losses; management has reduced exposure, capping motor growth.
Medical inflation and hospital fraud are squeezing margins; management is cautious on growth in this segment.
Mentioned in Q2 FY25, Q4 FY24
Management expects core premium growth to continue outpacing the industry, driven by disciplined underwriting.
Mentioned in Q3 FY24, Q4 FY24
Acquisition completed in April 2024; integration and utilization of Vidal network to begin next quarter.
Mentioned in Q1 FY24, Q2 FY24
Management expects NBV growth to sustain as par product mix improves and new bank partnerships contribute.
Mentioned in Q1 FY24, Q2 FY24
Analyst raised concern about sustainability of crop and government health business given competitive pricing and tender-based nature.
Mentioned in Q2 FY24, Q4 FY24
Growth in government health and crop is tender-based and pricing-dependent; management may lose share if pricing becomes unfavorable.
Management expects VNB to grow faster than top-line due to product structure changes and focus on profitability.
New surrender value guidelines have impacted product mix and distribution, with agency channel taking longer to adjust.
View Risks →